Abstract:Importance: Conflicting evidence exists on the association between azithromycin use and cardiac events. Objective: To compare the odds of cardiac events among new users of azithromycin relative to new users of amoxicillin using real-world data. Design, setting, and participants: This retrospective cohort study used data from Truven Health Analytics MarketScan database from January 1, 2009, to June 30, 2015. Patients receiving either amoxicillin or azithromycin and enrolled in a health care plan 365 days before (baseline period) the dispensing date (index date) were included in the study. Patients were matched 1:1 on high-dimensional propensity scores. Data were analyzed from October 1, 2018, to December 31, 2019. Exposures: New use of azithromycin compared with new use of amoxicillin. Main outcomes and measures: The primary outcome consisted of cardiac events, including syncope, palpitations, ventricular arrhythmias, cardiac arrest, or death as a primary diagnosis for hospitalization at 5, 10, and 30 days from the index date. Logistic regression models were used to estimate odds ratios (ORs) with 95% CIs. Results: After matching, the final cohort included 2 141 285 episodes of each index therapy (N = 4 282 570) (mean [SD] age of patients, 35.7 [22.3] years; 52.6% female). Within 5 days after therapy initiation, 1474 cardiac events (0.03%) occurred (708 in the amoxicillin cohort and 766 in the azithromycin cohort). The 2 most frequent events were syncope (1032 [70.0%]) and palpitations (331 [22.5%]). The odds of cardiac events with azithromycin compared with amoxicillin were not significantly higher at 5 days (OR, 1.08; 95% CI, 0.98-1.20), 10 days (OR, 1.05; 95% CI, 0.97-1.15), and 30 days (OR, 0.98; 95% CI, 0.92-1.04). Among patients receiving any concurrent QT-prolonging drug, the odds of cardiac events with azithromycin were 1.40 (95% CI, 1.04-1.87) greater compared with amoxicillin. Among patients 65 years or older and those with a history of cardiovascular disease and other risk factors, no increased risk of cardiac events with azithromycin was noted. Conclusions and relevance: This study found no association of cardiac events with azithromycin compared with amoxicillin except among patients using other QT-prolonging drugs concurrently. Although azithromycin is a safe therapy, clinicians should carefully consider its use among patients concurrently using other QT-prolonging drugs.

Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database

Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS

Analysis on 198 cases adverse drug reaction/event reports of azithromycin

The Efficacy and Safety of Azithromycin in Asthma: A Systematic Review

Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database

Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System

Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases

Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System

Risk of Mortality and Cardiovascular Events in Patients with Chronic Obstructive Pulmonary Disease Treated with Azithromycin, Roxithromycin, Clarithromycin, and Amoxicillin

Safety of azithromycin in pediatrics: a systematic review and meta-analysis

Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin

Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis

Analysis and Prevention of Liver Injury Caused by Azithromycin:a Retrospective Study of 27 Cases

Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

Antibiotics-associated pseudomembranous colitis: a disproportionality analysis of the US food and drug administration adverse event reporting system (FAERS) database

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

Safety analysis of quinolones use in minors-based on the FAERS database

Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database

High risks adverse events associated with usage of aspirin in chronic obstructive pulmonary disease

Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events.